Retrospective Evaluation of COVID-19 Therapeutics
Lecture Notes of the Institute for Computer Sciences, Social-Informatics and Telecommunications Engineering, LNICST, ISSN: 1867-822X, Vol: 451 LNICST, Page: 375-400
2022
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Conference Paper Description
The pandemic outbreak of COVID-19 created panic all over the world. As therapeutics that can effectively wipe out the virus and terminate transmission are not available, supportive therapeutics are the main clinical treatments for COVID-19. Repurposing available therapeutics from other viral infections is the primary surrogate in ameliorating and treating COVID-19. The therapeutics should be tailored individually by analyzing the severity of COVID-19, age, gender, comorbidities, and so on. We aim to investigate the effects of COVID-19 therapeutics and to search for laboratory parameters indicative of severity of illness. Multi-center collaboration and large cohort of patients will be required to evaluate therapeutics combinations in the future. This study is a single-center retrospective observational study of COVID-19 clinical data in China. Information on patients’ treatment modalities, previous medical records, individual disease history, and clinical outcomes were considered to evaluate treatment efficacy. After screening, 2,844 patients are selected for the study. The result shows that treatment with TCM (Hazard Ratio (HR) 0.191 [95% Confidence Interval (CI), 0.14–0.25]; p < 0.0001), antiviral therapy (HR 0.331 [95% CI 0.19–0.58]; p = 0.000128), or Arbidol (HR 0.454 [95% CI 0.34–0.60]; p < 0.0001) is associated with good prognostic of patients. Multivariate Cox regression analysis showed TCM treatment decreased the mortality hazard ratio by 69.4% (p < 0.0001).
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85151048130&origin=inward; http://dx.doi.org/10.1007/978-3-031-23902-1_29; https://link.springer.com/10.1007/978-3-031-23902-1_29; https://dx.doi.org/10.1007/978-3-031-23902-1_29; https://link.springer.com/chapter/10.1007/978-3-031-23902-1_29
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know